BRCA mutations in prostate cancer patients
Olmos, D.; Castro, E.
Clinical Advances in Hematology and Oncology H&o 11(9): 598-599
2013
ISSN/ISBN: 1543-0790 PMID: 24518526 Document Number: 668687
Document emailed within 1 workday
Related Documents
Bremer, M.; Steinmann, D.; Dork, T.; Borger, J.; Rades, D.; Karstens, J.H. 2001: Bilaterales Mammakarzinom und Lokalrezidiv: Prävalenz von BRCA-1- und BRCA-2-Genmutationen an einem unselektionierten Kollektiv - Bilateral breast cancer and local relapse: a hospital-based study of the prevalence of BRCA 1 and BRCA 2 gene Mutations Strahlentherapie und Onkologie 177(7): 325-329Triantafyllidou, O.; Vlachos, I.S.; Apostolou, P.; Konstantopoulou, I.; Grivas, A.; Panopoulos, C.; Dimitrakakis, C.; Kassanos, D.; Loghis, C.; Bramis, I.; Vlahos, N.; Yannoukakos, D.; Fostira, F. 2015: Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece Journal of BUON: Official Journal of the Balkan Union of Oncology 20(4): 978-984
Narod, S.A.; Sun, P.; Risch, H.A. 2001: Ovarian cancer, oral contraceptives, and BRCA mutations New England Journal of Medicine 345(23): 1706-1707
Grann, V. 1997: Risk of breast cancer in carriers of BRCA gene mutations New England Journal of Medicine 337(11): 788
Howard-McNatt, M. 2013: Pros and cons of screening for BRCA mutations North Carolina Medical Journal 74(6): 489-490
Ben David, Y.; Chetrit, A.; Hirsh-Yechezkel, G.; Friedman, E.; Beck, B.D.; Beller, U.; Ben-Baruch, G.; Fishman, A.; Levavi, H.; Lubin, F.; Menczer, J.; Piura, B.; Struewing, J.P.; Modan, B. 2002: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20(2): 463-466
Levavi, H.; Sabah, G. 2003: BRCA susceptibility genes--a review of current conservative management of BRCA mutation carriers European Journal of Gynaecological Oncology 24(6): 463-466
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Bit-Sava, E.M.; Belogurova, M.B.; Imianitov, E.N.; Balandov, S.G.; Korniushin, O.V.; Borisov, M.K. 2013: Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers Voprosy Onkologii 59(2): 5-11
O'Dell, K.J.; Volk, R.J.; Cass, A.R.; Spann, S.J. 1999: Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 48(9): 682-688
De la Taille, A.; Houlgatte, A.; Houdelette, P.; Berlizot, P.; Ramirez, J.; Ricordel, I. 1997: Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients) Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(2): 240-245
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Zhang, R.; Li, Y.; Chen, Y.; Liu, X.; Wang, Z.; Sun, H.; Zheng, Y.; Ding, Z.; Lan, L.; Li, M.; Qin, J.; Chen, X. 2015: Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer Zhonghua Yi Xue Za Zhi 95(47): 3839-3842
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148
Kolontarev, K.B.; Govorov, A.V.; Osipova, T.A.; Sidorenkov, A.V.; Pushkar, D.Yu. 2015: Value of the -2propsa Index and the Prostate Health Index in Patients with Prostate Cancer: Review of Literature and Data of Russian Prospective Study Urologiia 2015(1): 49-53
Carlson, K.; Chung, A.; Mirocha, J.; Donovan, C.; Estrada, S.; Siegel, E.; Giuliano, A.; Amersi, F. 2018: Menopausal Status and Outcomes of BRCA Mutation Carriers with Breast Cancer American Surgeon 84(10): 1584-1588
Gil, F. 1996: Hereditary breast cancer risk: factors associated with the decision to undergo BRCA 1 testing European Journal of Cancer Prevention: the Official Journal of the European Cancer Prevention Organisation 5(6): 488-490